UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Expression of Proinflammatory and Proangiogenic Cytokines in Patients with Head and Neck Cancer

Clinical cancer research, 1999-06, Vol.5 (6), p.1369-1379

1999

Volltextzugriff (PDF)

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

Annals of oncology, 2018-10, Vol.29, p.viii410-viii410

2018

Volltextzugriff (PDF)

S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6, p.90-91

2022

Volltextzugriff (PDF)

Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer

Journal of clinical oncology, 2001-02, Vol.19 (3), p.800-811

2001

Volltextzugriff (PDF)

Mammalian bombesin receptors

Medicinal research reviews, 1995-09, Vol.15 (5), p.389-417

1995

Volltextzugriff (PDF)

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

Annals of oncology, 2022-09, Vol.33, p.S905

2022

Volltextzugriff (PDF)

400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

Annals of oncology, 2022-11, Vol.33, p.S1598

2022

Volltextzugriff (PDF)

Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7028-7028

2004

Volltextzugriff (PDF)

73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Volltextzugriff (PDF)

1151PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study

Annals of oncology, 2018-12, Vol.29, p.x26-x26

2018

Volltextzugriff (PDF)

Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines

Clinical cancer research, 2005-02, Vol.11 (4), p.1572-1578

2005

Volltextzugriff (PDF)

Two amino acids in the sixth transmembrane segment of the mouse gastrin-releasing peptide receptor are important for receptor activation

The Journal of pharmacology and experimental therapeutics, 2000-09, Vol.294 (3), p.1053

2000

Volltextzugriff (PDF)

S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST‐IN‐HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6, p.90-91

2022

Volltextzugriff (PDF)

Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer

Journal of clinical oncology, 1998-02, Vol.16 (2), p.635-641

1998

Volltextzugriff (PDF)

Effect of Gastrin-Releasing Peptide Receptor Number on Receptor Affinity, Coupling, Degradation, and Modulation

Molecular pharmacology, 1997-05, Vol.51 (5), p.721-732

1997

Volltextzugriff (PDF)

An Aspartate Residue at the Extracellular Boundary of TMII and an Arginine Residue in TMVII of the Gastrin-Releasing Peptide Receptor Interact To Facilitate Heterotrimeric G Protein Coupling

Biochemistry (Easton), 1999-07, Vol.38 (29), p.9366-9372

1999

Volltextzugriff (PDF)

Phosphorylation uncouples the gastrin-releasing peptide receptor from G(q)

The Journal of biological chemistry, 1999-12, Vol.274 (51), p.36700-36706

1999

Volltextzugriff (PDF)

Vasoactive intestinal peptide increases intracellular cAMP and gonadotropin-alpha gene activity in JEG-3 syncytial trophoblasts. Constraints posed by desensitization

The Journal of biological chemistry, 1990-06, Vol.265 (18), p.10274-10281

1990

Volltextzugriff (PDF)

The Gastrin-releasing Peptide Receptor Is Rapidly Phosphorylated by a Kinase Other Than Protein Kinase C After Exposure to Agonist (∗)

The Journal of biological chemistry, 1995-04, Vol.270 (14), p.8217-8224

1995

Volltextzugriff (PDF)

Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5‐fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin‐3

Cancer, 1994-11, Vol.74 (10), p.2808-2810

1994

Volltextzugriff (PDF)

Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5037-5037

2009

Volltextzugriff (PDF)

Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7028-7028

2004

Volltextzugriff (PDF)

Alterations in Receptor Expression or Agonist Concentration Change the Pathways Gastrin-Releasing Peptide Receptor Uses to Regulate Extracellular Signal-Regulated Kinase

Molecular pharmacology, 2004-12, Vol.66 (6), p.1625-1634

2004

Volltextzugriff (PDF)

A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

EJC skin cancer, 2024, Vol.2, p.100213, Article 100213

2024

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(36)
magazinearticle
(1)

Sprache

Englisch
(37)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Expression of Proinflammatory and Proangiogenic Cytokines in Patients with Head and Neck Cancer

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer

Mammalian bombesin receptors

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro

73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study

1151PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study

Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines

Two amino acids in the sixth transmembrane segment of the mouse gastrin-releasing peptide receptor are important for receptor activation

S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST‐IN‐HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer

Effect of Gastrin-Releasing Peptide Receptor Number on Receptor Affinity, Coupling, Degradation, and Modulation

An Aspartate Residue at the Extracellular Boundary of TMII and an Arginine Residue in TMVII of the Gastrin-Releasing Peptide Receptor Interact To Facilitate Heterotrimeric G Protein Coupling

Phosphorylation uncouples the gastrin-releasing peptide receptor from G(q)

Vasoactive intestinal peptide increases intracellular cAMP and gonadotropin-alpha gene activity in JEG-3 syncytial trophoblasts. Constraints posed by desensitization

The Gastrin-releasing Peptide Receptor Is Rapidly Phosphorylated by a Kinase Other Than Protein Kinase C After Exposure to Agonist (∗)

Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5‐fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin‐3

Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma

Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro

Alterations in Receptor Expression or Agonist Concentration Change the Pathways Gastrin-Releasing Peptide Receptor Uses to Regulate Extracellular Signal-Regulated Kinase

A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

Suchergebnisse filtern